Melinta, Xediton partner to commercialise anti-infective products in Canada
Melinta Therapeutics and Xediton Pharmaceuticals have entered an exclusive commercialisation and licensing agreement for four novel anti-infective products.
📰 Priority Review News
Page 59 - Priority Review News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Priority Review. Real-time updates on events, politics, business and more.
Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases
Sulbactam-durlobactam is the first pathogen-targeted therapy under investigation for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by... | May 11, 2023
Source: marketscreener.com
Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of
Sulbactam-durlobactam is the first pathogen-targeted therapy under investigation for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter).WALTHAM, Mass.--(BUSINESS WIRE)--Inn...
United States Keith Kaye Jolla Pharmaceutical Company Drug Administration Securities Exchange Glaxo Group Limited
Source: pharmiweb.com
FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause
/PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Veozah (fezolinetant), an oral medication for the treatment of moderate to severe...
Janet Maynard Drug Administration Office Of Rare Diseases Astellas Pharma Us Inc Rare Diseases Reproductive Medicine
Source: prnewswire.com
FDA OKs New Drug for Hot Flashes
The first-in-class approval of fezolinetant (Veozah) is for treatment of moderate to severe vasomotor symptoms associated with menopause.
United States Astellas Pharma Endocrine Society Drug Administration Clinical Endocrinology North America
Source: medscape.com
FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause
The FDA approved Veozah (fezolinetant), an oral medication for the treatment of moderate to severe vasomotor symptoms, or hot flashes, caused by menopause. Veozah is the first neurokinin 3 receptor antagonist approved by the FDA to treat moderate to severe hot flashes from menopause.
Janet Maynard Human Services Astellas Pharma Us Inc Drug Administration Office Of Rare Diseases Us Department Of Health
Source: fda.gov
Galera Therapeutics : Company raised $30 million in gross proceeds from registered direct offering Company expanded commercial team and appointed leading biopharmaceutical executives with decades of experience successfully launching and commercializing new oncology products - Form 8-K
Company raised $30 million in gross proceeds from registered direct offering Company expanded commercial team and appointed leading biopharmaceutical executives... | May 11, 2023
Source: marketscreener.com
LianBio Announces Marketing Approval of CAMZYOS (mavacamten) in the Macau Special Administrative Region (SAR) of China
11.05.2023 - SHANGHAI, China and PRINCETON, N.J., May 11, 2023 (GLOBE NEWSWIRE) - LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that CAMZYOS ... Seite 1
Yizhe Wang China National Medical Products Administration Chief Executive Officer Priority Review New Drug Application Kansas City Cardiomyopathy Questionnaire
Source: wallstreet-online.de
SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress
STAMFORD, Conn., May 11, 2023 -- SpringWorks Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and... | May 11, 2023
United States Saqib Islam Jim Cassidy Samantha Hilson Sandler Dana Farber Cancer Institute Drug Administration
Source: marketscreener.com
Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
Received GSK royalties of $60.3 million, net product revenues of $11.5 million and license revenue of $8.0 million in the first quarter of 2023Repurchased $40.3 million of common stock and paid off $96.2 million of 2023 convertible notesBURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” o...
Acinetobacter Baumannii Calcoaceticus Pavel Raifeld Theravance Respiratory Company Securities Exchange Innoviva Inc Jolla Pharmaceutical Company
Source: pharmiweb.com